Articles By Jack Cush, MD
ACR 2026 Day 3 Report
Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:
Read Article
ACR 2026 – Day 2 Report
It's a wrap on Day 2 at ACR Convergence 2026. These five abstracts caught my eye.
Read Article
ACR 2026 – Day 1 Report
ACR Convergence was off to a big start with the year in review, posters and plenary sessions. Here are a few of my favorite presentations from todays Plenary I session at ACR Convergence.
Read Article
ACR 2026 – Big Pharma Brings Its Biggest Readouts to Orlando
ACR Convergence 2026 runs November 6–11 in Orlando, and the major companies will be presenting their highlight trials this week. Phase 3 results in Sjögren's and gout headline the late-breaking orals, while plenaries feature a head-to-head PsA trial and lupus nephritis biopsy data.
Read Article
ACR 2026 – Biotech and Mid-Size Companies Bet on Novel Mechanisms
ACR Convergence 2026 is crowded with first-in-class mechanisms: an oral IL-23 receptor peptide, FcRn blockade, a JAK head-to-head and a wave of cell depletion therapies. Top abstracts include (all times ET):Argenx
Read Article
3 x IL-23 = IL do Better (11.6.2026)
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
Read Article
Autologous HCT in Severe Systemic Sclerosis
An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation, adding important evidence on sustained positive clinical outcomes and long-term safety in patients treated for early severe systemic sclerosis.
Read Article
The Concern about Seronegative RA
A current review of seronegative RA (SNRA) by D’Onofrio, et al in npj Autoimmunity shows the diverse fate of seronegative RA - which can resolve, persist or become refractory. Clearly dedicated trials of SNRA are needed to better predict.
Read Article
FDA Approves Tildrakizumab for Psoriatic Arthritis
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
Read Article
Mixed Drinks, Mixed Results (10.30.2026)
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Read Article